The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
Schrodinger to offer Eli Lilly’s AI drug discovery platform on its software
By Sneha S K Jan 9 (Reuters) – Schrodinger said on Friday it is collaborating with Eli Lilly…
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog.…
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…
LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
NEW YORK, December 29, 2025, 17:45 ET — After-hours Shares of Eli Lilly and Company (LLY) were up…
China’s new commercial insurance model could broaden access to Alzheimer’s drugs
ChiÂna’s new comÂmerÂcial inÂsurÂance forÂmuÂlaÂry looks to exÂpand paÂtient acÂcess to Alzheimer’s disÂease medÂiÂcines from Eli LilÂly and…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…
Eli Lilly Scores Another Major Win: Time to Buy?
Eli Lilly’s next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…